Search

Dichromate

Arformoterol

The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients … using long-acting beta agonists for the treatment of asthma.

Angiotensin II

options for critically ill hypotensive patients who do not adequately respond to currently available therapies. … in adults with septic or other distributive shock.

Voxilaprevir

Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated

Human cord blood hematopoietic progenitor cell

bone marrow transplant setting, which may be due to "naive" nature of lymphocytes [A32223]. … mismatch due to expanded donor pool, which increases the chance of finding a suitable donor, particularly in patients requiring urgent transplantation [A32219].

Secukinumab

[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

Dequalinium

[A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation.

Orforglipron

or water restrictions. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.

Nivolumab

[L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.

Gadopiclenol

Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues